Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
Cancer Chemother Pharmacol
.
2016 Feb;77(2):439.
doi: 10.1007/s00280-015-2890-9.
Authors
Johanna C Bendell
1
,
Lee S Rosen
2
,
Robert J Mayer
3
,
Jonathan W Goldman
2
,
Jeffrey R Infante
4
,
Fabio Benedetti
5
,
Donghu Lin
6
,
Hirokazu Mizuguchi
5
,
Christopher Zergebel
5
,
Manish R Patel
7
Affiliations
1
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA. jbendell@tnonc.com.
2
University of California, 2020 Santa Monica Blvd., Suite 600, Santa Monica, CA, 90404, USA.
3
Dana-Farber Cancer Institute, 450 Brookline Ave., Dana 1602, Boston, MA, 02215, USA.
4
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA.
5
Taiho Oncology Inc., 202 Carnegie Center, Suite 100, Princeton, NJ, 08540, USA.
6
Taiho Pharmaceutical of Beijing Co., Ltd., 9F-9A3, Hanwei Plaza, 7th, Guanghua Rd., Chaoyang Dist., Beijing City, 100004, China.
7
Sarah Cannon Research Institute/Florida Cancer Specialists, 600 N. Cattlemen Road, Suite 200, Sarasota, FL, 34232, USA.
PMID:
26589791
PMCID:
PMC4969883
DOI:
10.1007/s00280-015-2890-9
No abstract available
Publication types
Published Erratum